These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 8331352)

  • 1. The effects of acute levodopa withdrawal on motor performance and dopaminergic receptor sensitivity in patients with Parkinson's disease.
    Turjanski N; Fernandez W; Lees AJ
    J Neurol Neurosurg Psychiatry; 1993 Jul; 56(7):771-5. PubMed ID: 8331352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levodopa consumption reduces dopaminergic receptor responsiveness in Parkinson's disease.
    Vaamonde J; Luquin MR; Obeso JA
    Clin Neuropharmacol; 1989 Aug; 12(4):271-84. PubMed ID: 2804991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease.
    Merello M; Lees AJ
    J Neurol Neurosurg Psychiatry; 1992 Nov; 55(11):1024-6. PubMed ID: 1469397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [On-off phenomena in Parkinson's disease. Continuous dopaminergic stimulation].
    Stocchi F; Ruggieri S; Baronti F; Bellantuono P; Brughita G; Antonini A; Bravi D; Agnoli A
    Clin Ter; 1987 Jul; 122(2):83-8. PubMed ID: 2973904
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of withdrawal of dopaminergic medication on simple and choice reaction time and the use of advance information in Parkinson's disease.
    Jahanshahi M; Brown RG; Marsden CD
    J Neurol Neurosurg Psychiatry; 1992 Dec; 55(12):1168-76. PubMed ID: 1362212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The motor response to sequential apomorphine in parkinsonian fluctuations.
    Hughes AJ; Lees AJ; Stern GM
    J Neurol Neurosurg Psychiatry; 1991 Apr; 54(4):358-60. PubMed ID: 2056323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenge tests to predict the dopaminergic response in untreated Parkinson's disease.
    Hughes AJ; Lees AJ; Stern GM
    Neurology; 1991 Nov; 41(11):1723-5. PubMed ID: 1944899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
    Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of motor response to apomorphine and levodopa in Parkinson's disease.
    Kempster PA; Frankel JP; Stern GM; Lees AJ
    J Neurol Neurosurg Psychiatry; 1990 Nov; 53(11):1004-7. PubMed ID: 2283512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical aspects of motor fluctuations in Parkinson's disease.
    Poewe WH
    Neurology; 1994 Jul; 44(7 Suppl 6):S6-9. PubMed ID: 8047260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlled-release transdermal apomorphine treatment for motor fluctuations in Parkinson's disease.
    Priano L; Albani G; Calderoni S; Baudo S; Lopiano L; Rizzone M; Astolfi V; Cavalli R; Gasco MR; Fraschini F; Bergamasco B; Mauro A
    Neurol Sci; 2002 Sep; 23 Suppl 2():S99-100. PubMed ID: 12548362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease.
    Mouradian MM; Heuser IJ; Baronti F; Chase TN
    Ann Neurol; 1990 Jan; 27(1):18-23. PubMed ID: 2301923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of withdrawal of dopaminergic medication in nursing home patients with advanced parkinsonism.
    Tse W; Frisina PG; Hälbig TD; Gracies JM; Liang L; Tarshish C; Lesser G; Neufeld R; Koller WC; Libow LS
    J Am Med Dir Assoc; 2008 Nov; 9(9):670-5. PubMed ID: 18992700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion.
    Solla P; Fasano A; Cannas A; Mulas CS; Marrosu MG; Lang AE; Marrosu F
    Parkinsonism Relat Disord; 2015 Aug; 21(8):968-71. PubMed ID: 26071817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.
    Bravi D; Mouradian MM; Roberts JW; Davis TL; Sohn YH; Chase TN
    Ann Neurol; 1994 Jul; 36(1):27-31. PubMed ID: 8024257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease.
    Zappia M; Montesanti R; Colao R; Branca D; Nicoletti G; Aguglia U; Quattrone A
    Mov Disord; 1997 Jan; 12(1):103-6. PubMed ID: 8990062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The dopaminergic response in multiple system atrophy.
    Hughes AJ; Colosimo C; Kleedorfer B; Daniel SE; Lees AJ
    J Neurol Neurosurg Psychiatry; 1992 Nov; 55(11):1009-13. PubMed ID: 1469394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous apomorphine in the treatment of Parkinson's disease.
    Frankel JP; Lees AJ; Kempster PA; Stern GM
    J Neurol Neurosurg Psychiatry; 1990 Feb; 53(2):96-101. PubMed ID: 2313313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.